0001213900-21-056413.txt : 20211103 0001213900-21-056413.hdr.sgml : 20211103 20211103140012 ACCESSION NUMBER: 0001213900-21-056413 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211103 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 211374760 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea149890-8k_inmedpharma.htm CURRENT REPORT
0001728328 false A1 0001728328 2021-11-03 2021-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 3, 2021

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

  

V6C 1B4

(Address of Principal Executive Offices)

  

(Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

 

Item 8.01 Other Events

 

On November 3, 2021, InMed Pharmaceuticals Inc. announced that it had filed an international patent application for the potential treatment of neurodegenerative diseases.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
99.1   News release, dated November 3, 2021
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: November 3, 2021 By:

/s/ Bruce Colwill

   

Bruce Colwill

Chief Financial Officer

     

 

 

2

 

 EX-99.1 2 ea149890ex99-1_inmed.htm NEWS RELEASE, DATED NOVEMBER 3, 2021

Exhibit 99.1

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

 

●Patent covers novel effects for neurodegenerative diseases
●Expands InMed’s patent portfolio with incremental rare cannabinoid

 

Vancouver, BC – November 3, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announced that it has filed an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.

 

This Patent Cooperation Treaty (PCT) application, entitled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids”, specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons. Furthermore, the PCT application also demonstrates the subject cannabinoid compound can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. The rare cannabinoid included in the PCT application is new to InMed’s portfolio.

 

“We are very encouraged by this initial data demonstrating potential for the use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and Huntington’s disease,” stated Dr. Eric Hsu, Senior Vice President Pre-Clinical Research & Development at InMed. “This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs. Expanding our patent portfolio to include, in addition to cannabinol (CBN), an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications demonstrates our continued commitment to our pharmaceutical programs and the potential of rare cannabinoids in medicine.”

 

This development further enhances InMed patent portfolio which currently includes twelve patent families focused on rare cannabinoids, seven of which address manufacturing technologies and five focusing on products/formulations. With the acquisition of BayMedica, the Company has expanded its patent portfolio to cover additional biosynthetic pathways as well as semi-synthetic production of both natural rare cannabinoids and cannabinoid analogs. BayMedica is continuing to develop a growing library of patentable, new cannabinoid analogs targeting diverse clinical applications.

 

The PCT is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 153 member countries within the PCT, enabling near-global patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, as well as many others.

 

 

 

 

Learn more about InMed’s Pharmaceutical Programs: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/

 

Learn more about InMed’s Cannabinoid Manufacturing Capabilities: https://www.inmedpharma.com/manufacturing/cannabinoid-manufacturing-capabilities/

 

About InMed: InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy

Senior Director, Investor Relations

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

Edison Group:

Joe Green/Laine Yonker

T: +1.646.653.7030/+1.646.653.7035

E: jgreen@edisongroup.com / lyonker@edisongroup.com

 

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs; that an identified rare cannabinoid may inhibit or slow the progression of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others; that an identified rare cannabinoid may promote neurite outgrowth and improve neuronal function; and continuing to develop a growing library of patentable, new cannabinoid analogs targeting diverse clinical applications.

 

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: continued economic, regulatory and market stability; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

 

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: regulatory filings may not be filed or approved on a timely basis, or at all. A more complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

 

 EX-101.SCH 3 inm-20211103.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 inm-20211103_def.xml XBRL DEFINITION FILE EX-101.LAB 5 inm-20211103_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20211103_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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ea149890-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2021-11-03 2021-11-03 iso4217:USD shares iso4217:USD shares 0001728328 false A1 8-K 2021-11-03 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver, B.C. CA V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 03, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 03, 2021
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver, B.C.
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea149890-8k_inmedpharma.htm ea149890ex99-1_inmed.htm inm-20211103.xsd inm-20211103_lab.xml inm-20211103_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea149890-8k_inmedpharma.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea149890-8k_inmedpharma.htm" ] }, "labelLink": { "local": [ "inm-20211103_lab.xml" ] }, "presentationLink": { "local": [ "inm-20211103_pre.xml" ] }, "schema": { "local": [ "inm-20211103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20211103", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea149890-8k_inmedpharma.htm", "contextRef": "From2021-11-03to2021-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea149890-8k_inmedpharma.htm", "contextRef": "From2021-11-03to2021-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001213900-21-056413-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-056413-xbrl.zip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